TradeFlare's AI research teams analysed XBI on 6 market nights between June 18, 2026 and August 4, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| August 4, 2026 | BUY | $147.31 | — / — | +4.1% | +7.6% | Potential for broad biotech sector recovery driven by innovation and M&A. |
| August 3, 2026 | BUY | $147.01 | — / — | +7.3% | +10.3% | Positive M&A activity in the biotech sector. |
| July 30, 2026 | BUY | $147.91 | — / — | +2.0% | +11.1% | The current market regime and the stock's technical and risk profiles do not support a buy recommendation. |
| July 21, 2026 | BUY | $150.94 | — / — | -3.1% | +3.6% | Positive sentiment driven by M&A and sector rotation in the biotech sector. |
| June 23, 2026 | BUY | $145.86 | — / — | +7.6% | +3.5% | The current market regime is neutral, and while XBI shows technical strength, the overall conviction across teams is not high enough for a buy. |
| June 18, 2026 | BUY | $139.39 | $156.12 / $129.63 | +10.4% | +7.3% | The 52-week breakout suggests potential for continued upward momentum over the coming weeks. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.